Terms: = Breast cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Treatment
147 results:
1. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
Roskoski R
Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
[TBL] [Abstract] [Full Text] [Related]
2. Inhibiting mek1 R189 citrullination enhances the chemosensitivity of docetaxel to multiple tumour cells.
Xue T; Fei S; Gu J; Li N; Zhang P; Liu X; Thompson PR; Zhang X
Philos Trans R Soc Lond B Biol Sci; 2023 Nov; 378(1890):20220246. PubMed ID: 37778380
[TBL] [Abstract] [Full Text] [Related]
3. Exosomes modified with anti-mek1 siRNA lead to an effective silencing of triple negative breast cancer cells.
Ferreira D; Santos-Pereira C; Costa M; Afonso J; Yang S; Hensel J; McAndrews KM; Longatto-Filho A; Fernandes R; Melo JB; Baltazar F; Moreira JN; Kalluri R; Rodrigues LR
Biomater Adv; 2023 Nov; 154():213643. PubMed ID: 37778291
[TBL] [Abstract] [Full Text] [Related]
4. Assessing the Antiproliferative Potential of a Novel Combretastatin A4 Derivative
Nazmy MH; Abu-Baih DH; Elrehany MA; Mustafa M; Aly OM; El-Sheikh AAK; Fathy M
Front Biosci (Landmark Ed); 2023 Aug; 28(8):185. PubMed ID: 37664933
[TBL] [Abstract] [Full Text] [Related]
5. A novel polypeptide CAPG-171aa encoded by circCAPG plays a critical role in triple-negative breast cancer.
Song R; Guo P; Ren X; Zhou L; Li P; Rahman NA; Wołczyński S; Li X; Zhang Y; Liu M; Liu J; Li X
Mol Cancer; 2023 Jul; 22(1):104. PubMed ID: 37408008
[TBL] [Abstract] [Full Text] [Related]
6. HDAC Inhibition Restores Response to HER2-Targeted Therapy in breast cancer via
Clayton NS; Carter EP; Fearon AE; Heward JA; Rodríguez Fernández L; Boughetane L; Wilkes EH; Cutillas PR; Grose RP
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047202
[TBL] [Abstract] [Full Text] [Related]
7. MIR497HG-Derived miR-195 and miR-497 Mediate Tamoxifen Resistance via PI3K/AKT Signaling in breast cancer.
Tian Y; Chen ZH; Wu P; Zhang D; Ma Y; Liu XF; Wang X; Ding D; Cao XC; Yu Y
Adv Sci (Weinh); 2023 Apr; 10(12):e2204819. PubMed ID: 36815359
[TBL] [Abstract] [Full Text] [Related]
8. Upregulation of the EGFR/mek1/MAPK1/2 signaling axis as a mechanism of resistance to antiestrogen‑induced BimEL dependent apoptosis in ER
Hagan ML; Mander S; Joseph C; McGrath M; Barrett A; Lewis A; Hill WD; Browning D; McGee-Lawrence ME; Cai H; Liu K; Barrett JT; Gewirtz DA; Thangaraju M; Schoenlein PV
Int J Oncol; 2023 Feb; 62(2):. PubMed ID: 36524361
[TBL] [Abstract] [Full Text] [Related]
9. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update.
Roskoski R
Pharmacol Res; 2023 Jan; 187():106552. PubMed ID: 36403719
[TBL] [Abstract] [Full Text] [Related]
10. A kinase inhibitor screen reveals mek1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERα-positive luminal breast cancer.
Wester L; Venneker S; Hazenoot M; Pont C; Koedoot E; Timmermans AM; Martens JWM; Jansen MPHM; Kockx CEM; van IJcken WFJ; Meerman JHN; Zhang Y; van de Water B
Biochem Pharmacol; 2022 Oct; 204():115233. PubMed ID: 36041543
[TBL] [Abstract] [Full Text] [Related]
11. Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways.
Wang F; Yuan C; Liu B; Yang YF; Wu HZ
J Transl Med; 2022 Jul; 20(1):310. PubMed ID: 35794555
[TBL] [Abstract] [Full Text] [Related]
12. Protein Tyrosine Phosphatase SHP2 Controls Interleukin-8 Expression in breast cancer Cells.
Amante RJ; Auf der Maur P; Richina V; Sethi A; Iesmantavicius V; Bonenfant D; Aceto N; Bentires-Alj M
J Mammary Gland Biol Neoplasia; 2022 Jun; 27(2):145-153. PubMed ID: 35739379
[TBL] [Abstract] [Full Text] [Related]
13. Oncogenic Long Noncoding RNA Linc01287 Promotes IGF1R Expression by Sponging miR-98 in breast cancer.
Guo C; Zhang M; Qian J; Li P; Guo L
Crit Rev Eukaryot Gene Expr; 2022; 32(3):31-44. PubMed ID: 35695608
[TBL] [Abstract] [Full Text] [Related]
14. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.
Roskoski R
Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994
[TBL] [Abstract] [Full Text] [Related]
15. RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative breast cancer.
Koh SB; Ross K; Isakoff SJ; Melkonjan N; He L; Matissek KJ; Schultz A; Mayer EL; Traina TA; Carey LA; Rugo HS; Liu MC; Stearns V; Langenbucher A; Saladi SV; Ramaswamy S; Lawrence MS; Ellisen LW
Clin Cancer Res; 2021 Sep; 27(17):4883-4897. PubMed ID: 34168046
[TBL] [Abstract] [Full Text] [Related]
16. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
[TBL] [Abstract] [Full Text] [Related]
17. Celastrol attenuates the inflammatory response by inhibiting IL‑1β expression in triple‑negative breast cancer cells.
You D; Jeong Y; Yoon SY; A Kim S; Kim SW; Nam SJ; Lee JE; Kim S
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846813
[TBL] [Abstract] [Full Text] [Related]
18. Interleukin-34-CSF1R Signaling Axis Promotes Epithelial Cell Transformation and breast Tumorigenesis.
Poudel M; Kim G; Bhattarai PY; Kim JY; Choi HS
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800170
[TBL] [Abstract] [Full Text] [Related]
19. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
Roskoski R
Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
[TBL] [Abstract] [Full Text] [Related]
20. Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor.
Chang TC; Matossian MD; Elliott S; Burks HE; Sabol RA; Ucar DA; Wathieu H; Zabaleta J; Del Valle L; Gill S; Martin E; Riker AI; Miele L; Bunnell BA; Burow ME; Collins-Burow BM
PLoS One; 2020; 15(10):e0226464. PubMed ID: 33035223
[TBL] [Abstract] [Full Text] [Related]
[Next]
